Nurs Res. 2022;71(5):404-410. doi: 10.1097/NNR.0000000000000599. Epub 2022 Apr 23.
Adolescent and young adult (AYA) cancer diagnoses are rising, and gains in survivorship are falling behind for this age group. Dose-limiting toxicities of therapy, including mucositis, are more frequent in this age group and may be contributing to poorer survivorship. Animal models and observational studies suggest that stress and inflammation may be contributing to the high prevalence of dose-limiting mucositis in this age demographic. The AYA oncology population has been an overlooked and underresearched oncology demographic, leading to poor understanding of why this age group has high side-effect burdens and poorer cancer survival.
This article describes a novel, prospective clinical study in AYAs receiving chemotherapy designed to evaluate if stress at the time of chemotherapy administration predicts the development of dose-limiting mucositis and determines if stress-induced inflammatory profiles mediate this relationship. This is the first study to translate these stress and inflammation findings from animal models to a nurse-centered research design in humans.
Persons aged 15-39 years who are receiving chemotherapy with a significant (>20%) risk of developing mucositis will be recruited for a prospective study. Baseline stress is measured through participant questionnaires, and blood is collected to analyze for inflammatory markers. Participants receive chemotherapy as clinically planned and complete a daily survey of mucositis symptoms for 14 days after chemotherapy. Regression and mediation analysis will determine if stress and inflammatory profiles predict the development of dose-limiting mucositis.
This model of inquiry through a nursing framework uses a biobehavioral model that considers physiological and psychological risk factors for chemotherapy toxicities. This study is also an important translational science study essential in bringing data from laboratory studies to the clinical arena. The study may also be important to implementation science because assessing the ability of critically ill individuals to participate in low-burden clinical studies may yield essential findings to improve care delivery.
Findings from this work will identify potentially modifiable factors that may be manipulated to minimize chemotherapy toxicities and lead to improved survival. Data from this study will inform larger research endeavors to better understand symptom development in this high-risk oncological population.
青少年和年轻成人(AYA)癌症诊断呈上升趋势,但该年龄段的生存获益却在下降。治疗的剂量限制毒性,包括黏膜炎,在该年龄段更为常见,可能导致生存获益较差。动物模型和观察性研究表明,应激和炎症可能是导致该年龄段高发剂量限制黏膜炎的原因。AYA 肿瘤人群一直是被忽视和研究不足的肿瘤人群,导致人们对为什么该年龄段副作用负担高且癌症生存率低的原因了解甚少。
本文描述了一项针对接受化疗的 AYA 患者的新型前瞻性临床研究,旨在评估化疗时的应激是否预测剂量限制黏膜炎的发生,并确定应激诱导的炎症特征是否介导这种关系。这是第一项将这些应激和炎症发现从动物模型转化为人类以护士为中心的研究设计的研究。
将招募年龄在 15-39 岁之间、接受化疗且有发生黏膜炎高风险(>20%)的患者进行前瞻性研究。通过参与者问卷测量基线应激,采集血液分析炎症标志物。参与者按照临床计划接受化疗,并在化疗后 14 天内每天完成黏膜炎症状调查。回归和中介分析将确定应激和炎症特征是否预测剂量限制黏膜炎的发生。
这种通过护理框架进行的探究模型采用了一种生物行为模型,考虑了化疗毒性的生理和心理风险因素。这项研究也是一项重要的转化科学研究,对于将实验室研究数据引入临床领域至关重要。该研究对于实施科学也可能很重要,因为评估危重患者参与低负担临床研究的能力可能会产生改善护理提供的重要发现。
这项工作的结果将确定可能被操纵以最小化化疗毒性并提高生存的潜在可调节因素。这项研究的数据将为更好地了解高危肿瘤人群的症状发展提供信息,并为更大规模的研究提供信息。